The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
21
MC Comac Medical
Sofia, Bulgaria
Budai Irgalmasrendi Korhaz
Budapest, Hungary
All Med - Lodz
Lodz, Poland
Ai Centrum Medyczne Sp. Z O.O. Sp.K.
Poznan, Poland
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Day 253
Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of LY3361237 During the Dosing Interval
PK: Cmin of LY3361237 During the Dosing Interval
Time frame: Day 1 predose through Day 253
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland
Pratia - Warsaw
Warsaw, Poland
Summit Clinical Research, s.r.o. - Bratislava
Bratislava, Slovakia